A case of a 45-year-old construction worker with a history of intravenous drug use, homelessness, and occasional alcohol and tobacco use.
CEO Todd Harris said the company has narrowed its focus to what he described as the “highest value opportunities” for its ...
LFT slightly high. There is no pain. No yellowing of the eyes. No weakness. So it is easy to brush it aside. But the liver rarely shouts in the beginning. It whispers.Liver Function Tests, or LFTs, ...
Fatty liver disease sounds mild, almost harmless. That name alone pushes many people into denial. There is usually no pain, ...
The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse modelALN1003 also ...
This report describes a female patient in her 60s with an immune-mediated necrotising myopathy (IMNM) occurring after semaglutide use. She was found to have progressive dysphagia, dysphonia, proximal ...
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), ...
Fatty liver disease is becoming increasingly common, yet many people still underestimate how serious it can be. Because the condition often develops quietly and without noticeable symptoms in its ...
Greetings, and welcome to the Rigel Pharmaceuticals Financial Conference Call for the Fourth Quarter and Full Year 2025. [Operator Instructions] As a reminder, this conference is being recorded. It is ...
Health and Me on MSN
Breaking 8 fatty liver myths that are ignored easily
Fatty liver disease is becoming increasingly common, yet many people still misunderstand what causes it and who is at risk. Because the condition often develops silently, it is easy to ignore early ...
NorthSea Therapeutics B.V. ("NorthSea" or the "Company"), a private, late-stage clinical biotechnology company leveraging its proprietary structurally engineered fatty acids (SEFAs) platform to ...
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results